This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Antibody drug conjugated with cytotoxic payload. antibody linked to a biologically active cytotoxic (anticancer) payload or drug 3d rendering. With the ultimate long-term goal of optimum dosing being determined before Phase 3 registration trials and before a drug is marketed. Cancer Cell [Internet].
About the author Dr Petra Dieterich, Senior Vice President at Abzena Petra has 30 years experience of in drugdevelopment in the pharmaceutical industry with a focus on supporting CMC activities. She has held leadership positions in Project Management, Technical Operations, and Business Development.
Jamie Rich, PhD is Senior Director of Technology, ADC Therapeutic Development at Zymeworks Inc. He has more than 17 years of experience in ADC and protein chemistry research and drugdevelopment. Dr Rich received a PhD in organicchemistry from the University of Alberta.
Now comes word of another absolutely incredible use of cryo-EM: determining with great ease and exquisite precision the structure of the smaller organic chemical compounds, or “small molecules,” that play such key roles in biological exploration and drugdevelopment.
After graduating, Miles went on to work as a scientist on AstraZeneca’s Research and Development graduate programme, working on projects in biocatalysis, computational organicchemistry and machine learning for drug discovery.
After earning my undergraduate degree from Connecticut College, followed by a PhD in organicchemistry from the University of Michigan, I landed a position as a researcher at a large biopharmaceutical company. The future of CMC lies in embracing more agile, science-driven approaches to drugdevelopment and manufacturing.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content